Caplin Point Laboratories Ltd

Caplin Steriles (CSL), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) Foscavir Injection from Clinigen Healthcare, (NDA 020068). Foscarnet Sodium Injection is an antiviral medication used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. According to IQVIATM (IMS Health), Foscarnet Sodium Injection, (6000 mg/250 mL Infusion Bag) had US sales of approximately $15 million for the 12-month period ending March 2026.

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.

Net profit of Caplin Point Laboratories rose 19.32% to Rs 170.11 crore in the quarter ended March 2026 as against Rs 142.57 crore during the previous quarter ended March 2025. Sales rose 19.45% to Rs 600.16 crore in the quarter ended March 2026 as against Rs 502.45 crore during the previous quarter ended March 2025. For the full year,net profit rose 19.57% to Rs 641.24 crore in the year ended March 2026 as against Rs 536.31 crore during the previous year ended March 2025. Sales rose 12.89% to Rs 2187.19 crore in the year ended March 2026 as against Rs 1937.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales600.16502.45 19 2187.191937.47 13 OPM %34.0333.45 -34.7933.39 - PBDT232.24193.71 20 875.56742.74 18 PBT213.44176.67 21 802.79676.78 19 NP170.11142.57 19 641.24536.31 20 Powered by Capital Market - Live

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.

The injection is a generic equivalent of the reference listed drug from Fresenius Kabi USA. The injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA data, the product had US sales of about $71 million for the 12-month period ended March 2026. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. The company's consolidated net profit rose 17.9% to Rs 163.88 crore while net sales increase 10.1% to Rs 542.77 crore in Q3 FY26 over Q3 FY25. Powered by Capital Market - Live

Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desmopressin Acetate Injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection, 4 mcg/mL of Nordic Pharma Inc., (NDA 018938). Desmopressin Acetate Injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus, helping to manage bleeding and regulate urine production. According to IQVIATM (IMS Health), Desmopressin Acetate injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials had US sales of approximately $26 million for the 12-month period ending December 2025. Powered by Capital Market - Live

The approval covers Sodium Phosphates Injection USP in strengths of 15mM P/5mL, 45mM P/15mL and 150mM P/50mL (3mM P/mL) single-dose vials. The product is a generic therapeutic equivalent of the Reference Listed Drug (RLD), approved under NDA 018892 and marketed by Hospira, Inc., USA. Sodium Phosphates Injection is indicated as a source of phosphorus for addition to large volume intravenous fluids to prevent or treat hypophosphatemia in patients with limited or no oral intake. It is also used in the preparation of customised parenteral nutrition formulations when standard electrolyte or nutrient solutions are inadequate to meet patient requirements. According to IQVIA (IMS Health) data, the approved strengths of Sodium Phosphates Injection recorded total US sales of approximately $67 million for the 12-month period ended December 2025. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. The company's consolidated net profit rose 17.9% to Rs 163.88 crore while net sales increase 10.1% to Rs 542.77 crore in Q3 FY26 over Q3 FY25. The counter declined 1.49% to Rs 1,706.90 on the BSE. Powered by Capital Market - Live

Net profit of Caplin Point Laboratories rose 17.93% to Rs 163.88 crore in the quarter ended December 2025 as against Rs 138.96 crore during the previous quarter ended December 2024. Sales rose 10.10% to Rs 542.77 crore in the quarter ended December 2025 as against Rs 492.96 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales542.77492.96 10 OPM %34.9432.92 - PBDT223.17193.46 15 PBT203.89177.26 15 NP163.88138.96 18 Powered by Capital Market - Live

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live

Net profit of Caplin Point Laboratories rose 18.08% to Rs 154.45 crore in the quarter ended September 2025 as against Rs 130.80 crore during the previous quarter ended September 2024. Sales rose 10.54% to Rs 534.04 crore in the quarter ended September 2025 as against Rs 483.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales534.04483.10 11 OPM %35.4234.08 - PBDT219.40185.22 18 PBT201.00168.46 19 NP154.45130.80 18 Powered by Capital Market - Live